Xenetic Biosciences, Inc. Stock: price and insider trades · United States
Xenetic Biosciences, Inc.: what insiders have been doing
Xenetic Biosciences, Inc. has a thin disclosure history in our data (latest filing: 23 April 2026). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 26,826 of 26,914 companies
3.8
score / 100
Value4
Quality4
FCF yld-51%
Earn yld-59%
EV/EBITDA·
ROE-47%
Gross mgn·
Net mgn-90%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.93
Analyst consensus
Income statement
RevenueUS$3M
EBITDA-US$2.8M-95% margin
Net income-US$2.7M-75.9% margin
Valuation
P/Book0.7x
Beta2.20
Balance sheet & cash
Market capUS$4.5M
Free Cash Flow-US$2.3M
Profitability & ownership
ROE-47.0%
ROA-26.8%
% insiders11.4%
% institutions6.5%
Last declaration on 23 April 2026
Declarations4 total
- 100,000 shares0Common StockSEC:0001683168-26-003163:0
- 93,390 shares0Common StockSEC:0001683168-19-002304:0
- 29,452 shares0Common StockSEC:0001662252-19-000014:0
- 50,000 shares0Common StockSEC:0001662252-17-000220:0
4 of 4 declarations
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapies for serious diseases. It leverages advanced technologies to enhance the effectiveness of treatments.
